Mirvaso (Brimonidine Tartrate)

Brimonidine is a selective alpha‑2 adrenergic receptor agonist. When applied to the skin, it activates these receptors on vascular smooth muscle, lowering cyclic AMP levels and causing the small blood vessels to constrict. This vasoconstriction reduces blood flow to the facial skin, thereby diminishing the redness characteristic of rosacea.

The dosing regimen for Mirvaso is determined by the prescribing healthcare professional. Typically, a thin layer is applied to the affected facial areas once daily, but the exact amount, frequency, and duration should follow the prescriber’s instructions and the product label.

Safety of Mirvaso during pregnancy and lactation has not been established. The product label advises avoiding use unless the potential benefit justifies the potential risk. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To order Mirvaso, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any necessary import documentation.

Mirvaso’s active ingredient, brimonidine, belongs to the alpha‑2 adrenergic agonist class, whereas many other topical rosacea agents, such as metronidazole or azelaic acid, act as anti‑inflammatory or antimicrobial agents. Brimonidine provides rapid, short‑term reduction of erythema through vasoconstriction, while the alternatives mainly target inflammation and may require longer treatment periods.

Mirvaso should be stored at room temperature, preferably below 25 °C, in its original tube. Keep the container tightly closed, protect it from direct sunlight and moisture, and avoid freezing. Do not use the product after the expiry date printed on the packaging.

Apply a thin layer of Mirvaso gel to the affected facial areas once daily, usually in the morning or as directed by a healthcare professional. Gently spread the gel over clean, dry skin, avoiding the eyes, mouth and any broken or irritated skin. Wash hands after application.

Serious but rare risks include allergic contact dermatitis, systemic hypotension from excessive absorption, and cardiovascular events such as chest pain or palpitations. Patients should seek immediate medical attention if they experience widespread rash, swelling, severe dizziness, or any signs of low blood pressure.

Mirvaso should not be used by individuals with known hypersensitivity to brimonidine tartrate or any component of the gel formulation. It is also contraindicated on broken, infected or severely inflamed skin, and should be avoided in patients where systemic vasoconstriction could be harmful, such as those with uncontrolled hypertension.